These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 16755161)

  • 1. The kind of vascular access influences the baseline inflammatory status and epoetin response in chronic hemodialysis patients.
    Movilli E; Brunori G; Camerini C; Vizzardi V; Gaggia P; Cassamali S; Scolari F; Parrinello G; Cancarini GC
    Blood Purif; 2006; 24(4):387-93. PubMed ID: 16755161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epoetin requirement does not depend on dialysis dose when Kt/N > 1.33 in patients on regular dialysis treatment with cellulosic membranes and adequate iron stores.
    Movilli E; Cancarini GC; Vizzardi V; Camerini C; Brunori G; Cassamali S; Maiorca R
    J Nephrol; 2003; 16(4):546-51. PubMed ID: 14696757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of C-reactive protein in patients on hemodialysis: a longitudinal study.
    Teruel JL; Marcen R; Ocaña J; Fernández-Lucas M; Rivera M; Tabernero G; Ortuño J
    Nephron Clin Pract; 2005; 100(4):c140-5. PubMed ID: 15855797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of iron deficiency in erythropoietin sensitivity in dialysis patients with elevated C-reactive protein].
    Martone M; Zanchi R; Panzetta G
    G Ital Nefrol; 2003; 20(1):31-7. PubMed ID: 12647284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.
    El-Khatib M; Duncan HJ; Kant KS
    Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A high calcium-phosphate product is associated with high C-reactive protein concentrations in hemodialysis patients.
    Movilli E; Feliciani A; Camerini C; Brunori G; Zubani R; Scolari F; Parrinello G; Cancarini GC
    Nephron Clin Pract; 2005; 101(4):c161-7. PubMed ID: 16103720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of vascular access type with inflammatory marker levels in maintenance hemodialysis patients.
    Dukkipati R; Molnar MZ; Park J; Jing J; Kovesdy CP; Kajani R; Kalantar-Zadeh K
    Semin Dial; 2014; 27(4):415-23. PubMed ID: 24118625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-reactive protein predicts vascular access thrombosis in hemodialysis patients.
    Chou CY; Kuo HL; Yung YF; Liu YL; Huang CC
    Blood Purif; 2006; 24(4):342-6. PubMed ID: 16601326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients.
    Leikis MJ; Kent AB; Becker GJ; McMahon LP
    Nephrology (Carlton); 2004 Jun; 9(3):153-60. PubMed ID: 15189176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Occult infection of old nonfunctioning arteriovenous grafts: a novel cause of erythropoietin resistance and chronic inflammation in hemodialysis patients.
    Nassar GM; Fishbane S; Ayus JC
    Kidney Int Suppl; 2002 May; (80):49-54. PubMed ID: 11982813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F; David S; Sala P; Icardi A; Casani A
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients.
    Locatelli F; Andrulli S; Memoli B; Maffei C; Del Vecchio L; Aterini S; De Simone W; Mandalari A; Brunori G; Amato M; Cianciaruso B; Zoccali C
    Nephrol Dial Transplant; 2006 Apr; 21(4):991-8. PubMed ID: 16384825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Nutritional status, comorbidity, and inflammation in hemodialysis].
    Fernández-Reyes MJ; Alvarez-Ude F; Sánchez R; Mon C; Iglesias P; Vázquez A
    Nefrologia; 2000; 20(6):540-9. PubMed ID: 11217649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microinflammation is involved in the dysfunction of arteriovenous fistula in patients with maintenance hemodialysis.
    Liu BC; Li L; Gao M; Wang YL; Yu JR
    Chin Med J (Engl); 2008 Nov; 121(21):2157-61. PubMed ID: 19080177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of vascular access type on outcome measures in patients on maintenance hemodialysis.
    Chand DH; Teo BW; Fatica RA; Brier M;
    Nephron Clin Pract; 2008; 108(2):c91-8. PubMed ID: 18212514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients.
    Bradbury BD; Critchlow CW; Weir MR; Stewart R; Krishnan M; Hakim RH
    Nephrol Dial Transplant; 2009 Mar; 24(3):919-25. PubMed ID: 18840893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Guidelines for the treatment of anemia in chronic renal failure].
    Triolo G;
    G Ital Nefrol; 2003; 20 Suppl 24():S61-82. PubMed ID: 14666504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular access outcomes in the elderly hemodialysis population: A USRDS study.
    Chan MR; Sanchez RJ; Young HN; Yevzlin AS
    Semin Dial; 2007; 20(6):606-10. PubMed ID: 17991212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary arteriovenous fistulas: converting prosthetic AV grafts to autogenous dialysis access.
    Slayden GC; Spergel L; Jennings WC
    Semin Dial; 2008; 21(5):474-82. PubMed ID: 18627564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.